NCI T32 Integrative Scholars Program
From left, Professor Jennifer Carew and student Madison Gamble meet in the Carew-Nawrocki Lab in the U of A Cancer Center administrative building.
Madison Gamble
Mentors: Jennifer Carew, PhD, and Sharad Khurana, MD
Madison Gamble is passionate about the development of novel cancer therapeutics because she wants her work to have a direct impact on patient outcomes.
She was awarded a highly competitive summer research internship at the major pharmaceutical company AstraZeneca as an undergraduate student. She chose the Carew and Nawrocki lab to pursue her dissertation research after joining U of A to further her training in therapeutic development.
“Every time I step into the lab, I’m able to see the potential of our discoveries with investigational therapies,” she said. “This is incredibly motivating for me.”
Gamble applied for the T32 training program because of its prestigious reputation and the unique, bench-to-bedside training experience it offers. “It aligns perfectly with my goal to develop a career as a translational cancer researcher,” she said.
Gamble’s research project is focused on investigating the mechanism of action of a novel drug candidate to treat acute myeloid leukemia. This agent was discovered at the U of A in partnership with the Arizona Center for Drug Discovery.
“Patients with AML desperately need new therapies, and I am excited that my project has the potential to address this critical need,” Gamble said.